Lumos Pharma — Q2 2022 Earnings Presentation
11 slides from Lumos Pharma's earnings presentation, Aug 10, 2022
Slide 1: Second Quarter 2022 Financial Results & Clinical Update
1 Second Quarter 2022 Financial Results & Clinical Update August 9, 2022
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this presentation are forward-looking statements within the meaning of The Private Securities Litigation Reform
Slide 3: Agenda
3 Agenda • Lisa Miller, Senior Director of Investor Relations • Rick Hawkins, Chief Executive Officer & Chairman • Rick Hawkins, Chief Executive Officer & Chairman • John McKew, PhD, President & Chief Scientific Officer • David B. Karpf, MD, Chief Medical Officer • Lori Lawley, Chief Financial Offic
Slide 4: Analyses Planned for OraGrowtH210 and OraGrowtH212 Trials
4 Analyses Planned for OraGrowtH210 and OraGrowtH212 Trials
Slide 5: OraGrowtH210 Trial: Phase 2 Trial in PGHD
5 OraGrowtH210 Trial: Phase 2 Trial in PGHD n = 20 Daily rhGH injection n = 20 LUM-201: 3.2 mg/kg/day n = 20 LUM-201: 1.6 mg/kg/day n = 20 LUM-201: 0.8 mg/kg/day • n = 80 • PEM(+) PGHD subjects • Inclusion: stim GH ≥ 5 ng/ml and baseline IGF-1 >30 ng/ml • rhGH treatment naïve • ~40 trial sites US &
Slide 6: Planning for Pivotal Phase 3 Trial of LUM-201 in PGHD – Tentative Trial Design
6 • n = ~150-200 • PEM(+) PGHD subjects • Inclusion: stim GH ≥ 5 ng/ml and baseline IGF-1 >30 ng/ml • rhGH treatment naïve • 12-month dosing • Global multi-site trial Planning for Pivotal Phase 3 Trial of LUM-201 in PGHD – Tentative Trial Design Primary Endpoint: • Achieve non-inferiority of LUM-201
Slide 7: OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD
7 • n = up to 24 • Open-label study • PGHD patients • rhGH-treatment naïve • Single, specialized clinical site • Q10 minute GH sampling for 12 hours OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD Primary Endpoints: • Assess LUM-201 effect on endogenous GH pulsatility and Annuali
Slide 8: LUM-201 Program Pipeline
8 LUM-201 Program Pipeline Study Pre-Clinical Phase 1 Phase 2 Phase 3 Status LUM-201 (Ibutamoren) In PGHD Phase 2 Ongoing Phase 2 trial: Interim analysis anticipated by year-end 2022 | Primary outcome data 2H2023 Long-term extension Proposed long-term extension study for OraGrowtH Trials PK/PD trial
Slide 9: PGHD is ~35% of the $3.4B Pediatric Recombinant Growth Hormone Market
9 PGHD is ~35% of the $3.4B Pediatric Recombinant Growth Hormone Market • Pediatric rhGH market projected to grow ~8% per year* • Well characterized market with established reimbursement mechanisms • Current SOC consists of daily injectables; expected to convert to weekly injectables • Pediatric rhG
Slide 10: Secure Cash Position
10 Secure Cash Position Cash balance to support current operations into Q2 2024, beyond primary outcome data readouts for OraGrowtH210 and OraGrowtH212 Trials Metric Position Cash balance June 30, 2022 $79.5 million Cash use through 2022 $8.5 to $9.5 million per quarter Strong financial position Cas
Slide 11: Investment Highlights
11 Investment Highlights PGHD = Pediatric Growth Hormone Deficiency * USA, Germany, France, Italy, Spain, UK, Japan (Grandview Research, Growth Hormone Market Forecast, 2019) Novel Oral Rare Disease Asset Pipeline in a Product Solid Financial Position • Novel oral therapeutic asset, LUM-201, for gro